AR085927A1 - Composiciones farmaceuticas intranasales de benzodiazepina - Google Patents

Composiciones farmaceuticas intranasales de benzodiazepina

Info

Publication number
AR085927A1
AR085927A1 ARP120101144A ARP120101144A AR085927A1 AR 085927 A1 AR085927 A1 AR 085927A1 AR P120101144 A ARP120101144 A AR P120101144A AR P120101144 A ARP120101144 A AR P120101144A AR 085927 A1 AR085927 A1 AR 085927A1
Authority
AR
Argentina
Prior art keywords
weight
pharmaceutical composition
pharmaceutical
methyl
pharmaceutical compositions
Prior art date
Application number
ARP120101144A
Other languages
English (en)
Original Assignee
Neuronex Inc
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronex Inc, Sk Biopharmaceuticals Co Ltd filed Critical Neuronex Inc
Publication of AR085927A1 publication Critical patent/AR085927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Abstract

Composiciones farmacéuticas intranasales que comprenden una benzodiazepina y métodos de uso de las mismas que pueden proporcionar un efecto terapéutico sin una reducción en la presión sanguínea y/o pulso tras la administración de la composición farmacéutica.Reivindicación 1: Una composición farmacéutica caracterizada porque comprende aproximadamente 1% a aproximadamente 15% en peso de una benzodiazepina o una sal aceptable para uso farmacéutico de la misma, aproximadamente 43% a aproximadamente 55% en peso de un glicol éter, aproximadamente 16% a aproximadamente 18% en peso de uno o más ésteres de ácidos grasos, aproximadamente 22% a aproximadamente 25% en peso de N-metil-2-pirrolidona, aproximadamente 1% a aproximadamente 5% en peso de agua, y aproximadamente 5% a aproximadamente 10% en peso de etanol. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque comprende aproximadamente 1% a aproximadamente 15% en peso de diazepam o una sal aceptable para uso farmacéutico del mismo, aproximadamente 43% a aproximadamente 55% en peso de dietilen glicol monoetiléter, aproximadamente 9% a aproximadamente 10% en peso de laurato de metilo, aproximadamente 7% a aproximadamente 9% en peso de monocaprilato de propilenglicol, aproximadamente 22% a aproximadamente 25% en peso de N-metil-2-pirrolidona, aproximadamente 1% a aproximadamente 5% en peso de agua, y aproximadamente 5% a aproximadamente 10% en peso de etanol. Reivindicación 25: La composición farmacéutica de cualquiera de las reivindicaciones 1 ó 10, caracterizada porque el glicol éter es dietilen glicol monoetil éter. Reivindicación 33: Un dispositivo para pulverización intranasal caracterizado porque comprende la composición farmacéutica de cualquiera de las reivindicaciones 1 - 32.
ARP120101144A 2011-03-31 2012-04-03 Composiciones farmaceuticas intranasales de benzodiazepina AR085927A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31

Publications (1)

Publication Number Publication Date
AR085927A1 true AR085927A1 (es) 2013-11-06

Family

ID=46928023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101144A AR085927A1 (es) 2011-03-31 2012-04-03 Composiciones farmaceuticas intranasales de benzodiazepina

Country Status (16)

Country Link
US (3) US20120252793A1 (es)
EP (1) EP2691100A4 (es)
JP (1) JP2014509655A (es)
KR (1) KR20140029426A (es)
CN (1) CN103619338B (es)
AR (1) AR085927A1 (es)
AU (1) AU2012236334B2 (es)
BR (1) BR112013024968A2 (es)
CA (1) CA2831308A1 (es)
HK (1) HK1195252A1 (es)
MX (1) MX357800B (es)
PH (1) PH12017501688A1 (es)
RU (2) RU2013148120A (es)
SG (2) SG10201602176RA (es)
TW (1) TWI601532B (es)
WO (1) WO2012135619A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
CA3064840A1 (en) * 2017-06-02 2018-12-06 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN111836615A (zh) 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
KR100715513B1 (ko) * 1999-07-26 2007-05-08 에스케이 코오포레이션 경비 항경련성 조성물
AU2002333785A1 (en) * 2002-09-03 2004-03-29 Pharmacure Health Care Ab Nasal sprays
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
CN101842079B (zh) * 2007-08-31 2012-09-05 阿基米德开发有限公司 非水性药物组合物
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP2013505248A (ja) * 2009-09-16 2013-02-14 アラーガン インコーポレイテッド 発作性疾患を治療するための組成物及び方法

Also Published As

Publication number Publication date
AU2012236334A1 (en) 2013-10-10
MX357800B (es) 2018-07-25
US20140128381A1 (en) 2014-05-08
MX2013011336A (es) 2013-12-16
EP2691100A4 (en) 2014-09-24
US20120252793A1 (en) 2012-10-04
CN103619338B (zh) 2016-06-22
WO2012135619A2 (en) 2012-10-04
SG193958A1 (en) 2013-11-29
TW201302204A (zh) 2013-01-16
PH12017501688A1 (en) 2018-09-10
TWI601532B (zh) 2017-10-11
AU2012236334B2 (en) 2017-02-16
JP2014509655A (ja) 2014-04-21
EP2691100A2 (en) 2014-02-05
WO2012135619A3 (en) 2012-11-22
CN103619338A (zh) 2014-03-05
RU2018135967A (ru) 2018-11-14
KR20140029426A (ko) 2014-03-10
BR112013024968A2 (pt) 2016-12-20
SG10201602176RA (en) 2016-04-28
HK1195252A1 (zh) 2014-11-07
CA2831308A1 (en) 2012-10-04
US20170151258A1 (en) 2017-06-01
RU2013148120A (ru) 2015-05-10

Similar Documents

Publication Publication Date Title
AR085927A1 (es) Composiciones farmaceuticas intranasales de benzodiazepina
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
UY32455A (es) Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
GT201400069A (es) Composiciones farmaceuticas
UY32833A (es) Antagonistas dp2 y usos del mismo
CL2013002673A1 (es) Composicion que comprende un polipéptido aislado con actividad inhibidor de nav1.3 y nav1.7; composicion farmacéutica que comprende la composicion antes dicha; metodo para tratar dolor.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
RS54898B1 (sr) Testosteronske formulacije
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
JP2014509655A5 (es)
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR082660A1 (es) Composiciones farmaceuticas para el tratamiento de enfermedades respiratorias e inflamatorias
NZ628079A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
UY31826A (es) Compuesto peptídico y su uso
ES2425998B1 (es) Composición para la limpieza y/o hidratación de la piel
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
AR095538A1 (es) Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oral

Legal Events

Date Code Title Description
FB Suspension of granting procedure